drugset / Trial / NCT02721459
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
Phase 1
Active not recruiting
26 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Exelixis · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of XL888 when administered orally with vemurafenib plus cobimetinib in participants with BRAF V600 mutated melanoma and to evaluate the safety and tolerability of this combination.
Timeline
- Start
- 2016-09-07
- Primary completion
- 2019-10-31
- Completion
- 2026-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cobimetinib | Small molecule | 40 mg | Oral |
| Subject | Vemurafenib | Small molecule | 720 mg | Oral |
| Subject | XL888 | Small molecule | 30 mg | Oral |
| Subject | XL888 | Small molecule | 45 mg | Oral |
| Subject | XL888 | Small molecule | 60 mg | Oral |
| Subject | XL888 | Small molecule | 90 mg | Oral |